Form 4: Pfizer Director James C. Smith Acquires Phantom Stock Units

Pfizer Inc. director James C. Smith was granted 7,686.539 phantom stock units as part of the company's deferred compensation plan for non-employee directors.

Summary

• Director James C. Smith acquired 7,686.539 phantom stock units on April 23, 2026.
• The units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• Each unit represents one phantom share of common stock valued at $26.67 per unit.
• Following this transaction, the director's total beneficial ownership of phantom stock units is 178,111.302.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Demonstrates alignment of director interests with long-term shareholder value through equity-linked compensation.

Negatives

• None identified.

Risks

• The value of the phantom stock units is tied to the future performance of Pfizer common stock.

Future Outlook

The units are settled in cash or common stock at the director's election following their retirement from the Board of Directors.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation, common among large-cap pharmaceutical companies to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The use of deferred compensation plans for non-employee directors is a standard governance practice among S&P 500 companies, including peers like Merck and Bristol Myers Squibb.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation arrangement.

Next Steps

• The units will be settled upon the director's retirement from the Board.

Key Dates

Keywords

Pfizer, PFE, Form 4, Insider Trading, Director Compensation, Phantom Stock